Table 4
Influence of retinectomy on IOP lowering medication
| Preop | Preop | >48 month | >48 month | |
|---|---|---|---|---|
| Diagnosis | Syst CAI | Topical (No of medications) | Syst CAI | Topical |
| *In 3/5 cases the follow up was not completed. 2 cases required systemic CAI and topical treatment, but maintained successful IOP control under that medication. | ||||
| Neovascular glaucoma | 8/12 | mean 1.3 | none | 7/12 none |
| 1/12 drozolamide and β blocking agent | ||||
| Trauma | 5/7 | mean 1.5 | none | 4/7 none |
| 2/7 drozolamide and β blocking agent | ||||
| 1/7 drozolamide | ||||
| Uveitis | 5/7 | mean 2 | none | none (2 patients steroids) |
| Glaucoma due to aphakia in congenital cataracts | 8/13 | mean 2.5 | none | 7/13 none |
| 2/13 drozolamide | ||||
| 1/13 drozolamide and β blocking agent | ||||
| Others | 2/5 | mean 2.8* | 2/5 * | 2/5 triple treatment |
| Juvenile and infantile glaucoma, Ehlers-Danlos syndrome | ||||
